Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) does about 4.89M shares in volume on a normal day but saw 1819291 shares change hands in Tuesday trading. The company now has a market cap of 1.26B USD. Its current market price is $8.07, marking an increase of 0.62% compared to the previous close of $8.02. The 52 week high reached by this stock is $15.70 whilst the lowest price level in 52 weeks is $7.79.
Ironwood Pharmaceuticals Inc (IRWD) has a 20-day trading average at $8.54 and the current price is -48.60% off the 52-week high compared with 3.59% distance from its 52-week low. The 50-day simple moving average of the closing price is $11.40 and its 200-day simple moving average is $10.51. If we look at the stock’s price movements over the week, volatility stands at 3.44%, which increases to 4.28% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 30.50 to suggest the stock is neutral.
The consensus objective for the share price is $18.00, suggesting that the stock has a potential upside of 55.17% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 17, 2024 when Craig Hallum initiated the stock to “Buy” and issued a price target of $21. Jefferies initiated its price target at $21.
Ironwood Pharmaceuticals Inc (IRWD) stock is down -1.82% over the week and -10.43% over the past month. Its price is -29.46% year-to-date and -25.83% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of -$0.01 below consensus estimates by -$0.22. IRWD’s earnings per share are forecast to grow by 110.50% this year and 19.10% over next year. Expected sales for next quarter are $112.16 million, which analysts say will come at $448.27 million for the current fiscal year and next year at $488.2 million. In addition, estimates put the company’s current quarterly revenue at an average of $106.3 million.
To reach the target analysts have set, the stock logically needs to grow 55.17 percent from here.
Outstanding shares total 156.35M with insiders holding 2.08% of the shares and institutional holders owning 108.88% of the company’s common stock. The company has a return on investment of -601.74% and return on equity of -654.88%. The forward price to earnings ratio is 10.12. The beta has a value of 0.56. Price to sales ratio is 2.85.
